The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ...

Redmond, founder and CEO of Dr. Stephanie’s Supplements, showcased her products, which she described as the latest innovations in supplement options for hormone and metabolic health, including a ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Researchers have found that a certain type of fibre found in oats and barley can lead to weight loss in the same way as drugs ...

Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.